EUVIMEDEUVIMED entdecken
Crossref

In vivo reprogramming of cytotoxic effector CD8 T cells via fractalkine-conjugated mRNA-LNPs

Angela R Corrigan iD, Shin Foong Ngiow iD, Maura Statzu iD, Amie Albertus iD, M Betina Pampena iD, Jayme M L Nordin iD, Stephen D Carro iD, Justin Harper iD, Rachelle L Stammen iD, Jennifer Wood iD, Houping Ni iD, Justin Su iD und 12 weitere

Science Immunology · 29.05.2026 · 11 (119)

DOI: 10.1126/sciimmunol.aec3436 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Immunology, erschienen am 29.05.2026. Verfasst von Angela R Corrigan und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, University of Pennsylvania, Philadelphia, PA, USA. Hauptthemen laut MEDLINE: RNA, Messenger, Chemokine CX3CL1, Nanoparticles, T-Lymphocytes, Cytotoxic. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 73 Literaturangaben. Gefördert von: National Institutes of Health, Office of Research Infrastructure Programs, National Institutes of Health, National Institute of Allergy and Infectious Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Selective in vivo reprogramming of cytotoxic effector CD8 T (T eff ) cells holds tremendous promise as a therapeutic tool but has not yet been accomplished. Here, we demonstrate that fractalkine-conjugated mRNA lipid nanoparticles (mRNA-LNPs) can specifically target and deliver mRNA to CX3CR1 + T eff cells in vitro and in vivo. In mice, fractalkine-conjugated mRNA-LNPs targeted up to 95% of blood and splenic T eff cells. In addition, delivery of IL-2–encoding mRNA and human CD62L-encoding mRNA to mouse T eff cells enabled robust exogenous IL-2 secretion and CD62L expression. In rhesus macaques, fractalkine-conjugated mRNA-LNPs targeted up to ~100% of peripheral blood T eff cells, and delivery of human CD62L-encoding mRNA enabled cell-surface human CD62L expression on peripheral blood T eff cells and detection of human CD62L + T eff cells in lymphoid tissue. Collectively, these data demonstrate the potential of natural receptor ligand-based targeting of mRNA-LNPs for rapid, efficient, and transient in vivo modification of T eff cells.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RNA, MessengerChemokine CX3CL1NanoparticlesT-Lymphocytes, CytotoxicCD8-Positive T-LymphocytesAnimalsHumansMiceMacaca mulattaL-SelectinMice, Inbred C57BLLiposomes

Substanzen

RNA, MessengerChemokine CX3CL1L-SelectinLipid NanoparticlesLiposomes

Autor:innen und Institutionen

  • Department of Microbiology, University of Pennsylvania, Philadelphia, PA, USA.
  • Institute for Immunology and Immune Health, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Parker Institute for Cancer Immunotherapy, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Division of Microbiology and Immunology, Emory National Primate Research Center, Emory University, Atlanta, GA, USA.
  • Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA.

ORCID-Profile: Angela R Corrigan, Shin Foong Ngiow, Maura Statzu, Amie Albertus, M Betina Pampena, Jayme M L Nordin, Stephen D Carro, Justin Harper, Rachelle L Stammen, Jennifer Wood, Houping Ni, Justin Su, Vladimir V Shuvaev, Victor Alcalde, Mohammed-Alkhatim A Ali, Jacob T Hamilton, Vincent H Wu, Mirko Paiardini, Drew Weissman, E John Wherry, Edward F Kreider, Michael R Betts

Förderung

  • National Institutes of Health
  • Office of Research Infrastructure Programs, National Institutes of Health
  • National Institute of Allergy and Infectious Diseases
  • Penn Measey Scholar in Molecular Medicine fund
  • BEAT-HIV consortium
  • Mark Foundation For Cancer Research
  • Parker Institute for Cancer Immunotherapy

Zitieren

APA

Corrigan, A. R., Ngiow, S. F., Statzu, M., Albertus, A., Pampena, M. B., Nordin, J. M. L., Carro, S. D., Harper, J., Stammen, R. L., Wood, J., Ni, H., Su, J., Hajialyani, M., Shuvaev, V. V., Alcalde, V., Ali, M. A., Hamilton, J. T., Ramalingam, R., Wu, V. H., …, & Betts, M. R. (2026). In vivo reprogramming of cytotoxic effector CD8 T cells via fractalkine-conjugated mRNA-LNPs. Science Immunology, 11(119). https://doi.org/10.1126/sciimmunol.aec3436

Vancouver

Corrigan AR, Ngiow SF, Statzu M, Albertus A, Pampena MB, Nordin JML, et al. In vivo reprogramming of cytotoxic effector CD8 T cells via fractalkine-conjugated mRNA-LNPs. Science Immunology. 2026;11(119). doi:10.1126/sciimmunol.aec3436

BibTeX
@article{Corrigan2026,
  author = {Corrigan, Angela R and Ngiow, Shin Foong and Statzu, Maura and Albertus, Amie and Pampena, M Betina and Nordin, Jayme M L and Carro, Stephen D and Harper, Justin and Stammen, Rachelle L and Wood, Jennifer and Ni, Houping and Su, Justin and Hajialyani, Marziyeh and Shuvaev, Vladimir V and Alcalde, Victor and Ali, Mohammed-Alkhatim A and Hamilton, Jacob T and Ramalingam, Rajesvaran and Wu, Vincent H and Paiardini, Mirko and Weissman, Drew and Wherry, E John and Kreider, Edward F and Betts, Michael R},
  title = {In vivo reprogramming of cytotoxic effector CD8 T cells via fractalkine-conjugated mRNA-LNPs},
  journal = {Science Immunology},
  year = {2026},
  volume = {11},
  number = {119},
  doi = {10.1126/sciimmunol.aec3436}
}
Kostenlos starten →